ArticleClinical drug investigation2005
Fluoroquinolone therapy for uncomplicated skin and skin structure infections : a retrospective database comparison of treatment duration, failures and charges.
Article in Clinical drug investigation, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it, 1 citations in OpenAlex.
- Fluoroquinolone-Associated Tendinopathy of the Hand and Wrist: A Systematic Review and Case Report.Hand (New York, N.Y.) · 2017Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveUncomplicated skin and skin structure infections (uSSSIs) are highly prevalent and costly. With the rising prevalence of bacterial resistance to older antibacterials, there has been an increase in the use of fluoroquinolones for the treatment of uSSSIs creating the need for comparative information. The objective of this study was to compare, under real-world conditions, the treatment duration, failure rates and treatment charges associated with initiation of outpatient treatment for uSSSIs with moxifloxacin versus levofloxacin.
methodsThis retrospective study was conducted using claims data (April 1999 through March 2002) from the PharMetrics Patient-Centric Database. A cohort was created of patients who had treatment for a uSSSI that was initiated with either moxifloxacin or levofloxacin. The endpoints evaluated were: treatment duration, treatment failure and total charges. Logistic and ordinary least-squares regression analyses were used to test for differences among treatment groups whilst controlling for demographic and clinical characteristics.
results506 patients were identified, representing 517 uSSSI treatment episodes. The mean durations of monotherapy and all antibacterial prescription therapy were significantly shorter for the moxifloxacin than the levofloxacin group (differences of 1.97 days [p = 0.015] and 1.60 days [p = 0.036], respectively). The original prescription duration, treatment failure rate and treatment charges were lower for the moxifloxacin group than the levofloxacin group, but differences were not statistically significant (p = 0.241, 0.395 and 0.199, respectively).
conclusionIn general, patients who initiated therapy for a uSSSI with moxifloxacin had a shorter duration of antibacterial therapy than those who initiated treatment with levofloxacin, with comparable treatment failure and cost outcomes. When a fluoroquinolone is required for the treatment of a uSSSI, moxi- floxacin (which is approved for 7-day therapy) provides comparable outcomes to levofloxacin under real-world conditions.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.